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Abstract
Introduction: While it has been reported that the risk of contralateral breast cancer in patients from BRCA1 or
BRCA2 positive families is elevated, little is known about contralateral breast cancer risk in patients from high risk
families that tested negative for BRCA1/2 mutations.
Methods: A retrospective, multicenter cohort study was performed from 1996 to 2011 and comprised 6,235 women
with unilateral breast cancer from 6,230 high risk families that had tested positive for BRCA1 (n = 1,154) or BRCA2 (n =
575) mutations or tested negative (n = 4,501). Cumulative contralateral breast cancer risks were calculated using the
Kaplan-Meier product-limit method and were compared between groups using the log-rank test. Cox regression analysis
was applied to assess the impact of the age at first breast cancer and the familial history stratified by mutation status.
Results: The cumulative risk of contralateral breast cancer 25 years after first breast cancer was 44.1% (95%CI,
37.6% to 50.6%) for patients from BRCA1 positive families, 33.5% (95%CI, 22.4% to 44.7%) for patients from BRCA2
positive families and 17.2% (95%CI, 14.5% to 19.9%) for patients from families that tested negative for BRCA1/2
mutations. Younger age at first breast cancer was associated with a higher risk of contralateral breast cancer. For
women who had their first breast cancer before the age of 40 years, the cumulative risk of contralateral breast
cancer after 25 years was 55.1% for BRCA1, 38.4% for BRCA2, and 28.4% for patients from BRCA1/2 negative families.
If the first breast cancer was diagnosed at the age of 50 or later, 25-year cumulative risks were 21.6% for BRCA1,
15.5% for BRCA2, and 12.9% for BRCA1/2 negative families.
Conclusions: Contralateral breast cancer risk in patients from high risk families that tested negative for BRCA1/2
mutations is similar to the risk in patients with sporadic breast cancer. Thus, the mutation status should guide
decision making for contralateral mastectomy.
Introduction
Women carrying a deleterious BRCA1 or BRCA2 mutation
not only face a strongly elevated lifetime risk for the devel-
opment of breast and ovarian cancer but also for a second
breast cancer [1,2]. The majority of second primaries
develop in the contralateral breast while ipsilateral breast
cancer is not significantly increased [3,4]. Estimates for
contralateral breast cancer range from 15% to 40% within
10 years [1,3,5-10]. Due to this wide range of risk esti-
mates, it is clinically important to identify predictive
factors. In a retrospective cohort study comprising 2,020
women with unilateral breast cancer from 978 families
with a BRCA1 or BRCA2 mutation, we could show that
contralateral breast cancer depends on the affected BRCA
gene and age at onset of the first breast cancer [5]. In a
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recent retrospective update on 810 breast cancer patients
from BRCA1/2 positive families, Metcalfe et al. as well as
previous studies also showed that prophylactic bilateral
salpingo-oophorectomy (PBSO) under the age of 50 years
reduces the risk of contralateral breast cancer by half
[9,10]. They further demonstrated that as the number of
first degree relatives under the age of 50 years with breast
cancer increases the risk of contralateral breast cancer also
increases. Data on other factors that may modify contralat-
eral breast cancer risk, for example tamoxifen use, are
inconsistent [10,11].
While the risk for second primaries has been studied in
BRCA1 or BRCA2 mutation carriers, preliminary data
indicate that the risk of contralateral breast cancer is not
significantly elevated in patients with familial breast can-
cer, who tested negative for BRCA1/2 mutations [12,13].
Despite these data and although the latter group accounts
for the majority of women with familial breast cancer,
there is a rising demand for prophylactic bilateral or
prophylactic contralateral mastectomy in these women
[14,15]. To question the need for this prophylactic
approach, in this article we extended our previously pub-
lished data on contralateral breast cancer risks and predic-
tive factors in two dimensions. First, we updated the
number of analyzed women from families with BRCA1 or
BRCA2 mutations. Second, we included women from
non-BRCA1/2 high risk families in the analysis for the first
time. These risk estimates can be used for counselling in
order to allow women to make a non-directive and
informed decision on the extent of surgical treatment and
secondary prevention.
Methods
German Consortium for Hereditary Breast and Ovarian
Cancer
Data were collected within the German Consortium for
Hereditary Breast and Ovarian Cancer which comprises
12 university based centers, as previously described [5].
Inclusion criteria and methods for genetic testing are
described elsewhere [16,17]. It is worth mentioning that
24% of all families that fulfill the inclusion criteria of the
German Consortium for Hereditary Breast and Ovarian
Cancer tested positive for a deleterious BRCA1 or BRCA2
mutation which reflects stringent inclusion criteria [16,17].
The study has been approved by the institutional review
boards of all participating centers. All patients gave their
written informed consent prior to study inclusion.
From 1996 to July 2011 a total of 8,733 families were
registered and tested positive for BRCA1 (n = 1,743) or
BRCA2 (n = 818) mutations or tested negative (n = 6,172).
For this updated retrospective cohort study all index cases
and their first- and second-degree relatives with a history
of unilateral breast cancer diagnosed after 1960 were
selected (12,897 patients from 6,364 families). Individuals
were excluded if their first breast cancer diagnosis was
bilateral (synchronous bilateral breast cancer). Individuals
were only selected from that branch of the family in which
the pathogenic mutation was detected or familial cluster-
ing of cancers was observed. All index patients, defined as
the earliest accessible affected family member and diag-
nosed with breast or ovarian cancer, were tested for
BRCA1/2 mutations. Of the selected relatives of BRCA1/2
mutation carriers, 328 (16%) could be proven to be car-
riers. Forty relatives who tested negative for the known
mutation in the family were considered phenocopies and
were excluded. All other relatives, whose mutation status
could not be determined, were considered putative car-
riers. An additional 392 patients (3.0%) were excluded due
to insufficient information regarding age at cancer events
or surgery (for example, bilateral mastectomy). In sum-
mary, 12,465 women with unilateral first breast cancer
diagnosis were included in the present analysis, compris-
ing 6,230 index patients and 6,235 relatives. Medical and
pathological records could be obtained from 83% of the
index patients and 47% of the relatives. For all other indi-
viduals information about medical history was obtained
through structured interviews. The study was performed
retrospectively. Prospective follow-up after recruitment is
not considered in this analysis. For the analysis, patients
were followed from their first unilateral breast cancer until
contralateral breast cancer or censoring.
For the comparison of contralateral breast cancer risk
in BRCA1 and 2 mutation carriers and BRCA1/2-nega-
tive women at high risk we used data from breast cancer
registries [18,19].
Statistical analysis
BRCA1, BRCA2 and non-BRCA1/2 families were analyzed
as previously described [5]. In summary, cumulative con-
tralateral breast cancer risks were calculated using the
Kaplan-Meier product-limit method and compared
between groups using the log-rank test. Cox proportional
hazards regression was used to analyze the association with
potential risk factors by estimation of hazard ratios (HR)
and their 95% CIs. All subjects were censored at the time
of second unilateral breast cancer, ovarian cancer, bilateral
mastectomy, death, or last observation, whichever occurred
first. We censored at unilateral breast cancer and ovarian
cancer because an effect of chemotherapy for these cancers
on the risk of subsequent contralateral breast cancer can
not be excluded. All reported P-values are two-sided.
P-values below 0.05 were considered statistically significant.
IBM SPSS Statistics 20.0.0.1 was used for all data analyses.
Results
Characteristics of the study population
Basic characteristics of the index patients and their relatives
are shown in Table 1. Index patients had a younger median
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age at first unilateral breast cancer and a considerably
higher risk for contralateral breast cancer than their rela-
tives (Figure 1). This was true for the whole study cohort
as well as for the three subgroups, that is, BRCA1 positive,
BRCA2 positive and BRCA1/2 negative families, and is
most likely due to the selection of index patients based on
clinical criteria, that is, DNA testing was preferentially per-
formed in those patients with clinical phenotypes that were
more indicative of a BRCA mutation. Thus, in order to
avoid overestimating the risks of contralateral breast can-
cer, index patients were excluded from further analyses.
Risk of contralateral breast cancer depending on
mutation status
In 6,235 relatives of index patients, 502 contralateral breast
cancers were observed. The total observation time from
first breast cancer until contralateral breast cancer or cen-
soring was 48,390 person-years. Figure 2A shows the dis-
tribution of age at first breast cancer for relatives of
families with BRCA1 and BRCA2 mutations and of
BRCA1/2 negative families. Relatives of families with
BRCA1 mutations were significantly younger at first breast
cancers than those from families with BRCA2 mutations
(P < 0.001) and both were significantly younger than
patients from BRCA1/2 negative families (P < 0.001 and
P < 0.001, respectively). Likewise, the age at contralateral
breast cancer was also significantly lower in the BRCA1
group than the BRCA2 group (P < 0.001) and the BRCA1/
2 negative group (P < 0.001) (Figure 2B). Analyses of the
time from first breast cancer to contralateral breast cancer
showed that contralateral breast cancer risk was signifi-
cantly higher in women from families with a BRCA1
mutation compared to women from families with a
BRCA2 mutation and compared to women from families
without a BRCA mutation (Figure 2C). Members of
families with BRCA1 mutations had a threefold (95%CI,
2.5 to 3.6) higher risk of contralateral breast cancer than
members of families without BRCA1/2 mutations. For
members of families with BRCA2 mutations the risk was
1.6-fold (95% CI, 1.2 to 2.2) higher than the risk for mem-
bers of families without BRCA1/2 mutations. The 25-year
cumulative risk of contralateral breast cancer after first
breast cancer was 44.1% (95%CI, 37.6% to 50.6%) for rela-
tives from families with a BRCA1 mutation, 33.5% (95%CI,
22.4% to 44.7%) for relatives from families with a BRCA2
mutation and 17.2% (95%CI, 14.5% to 19.9%) for relatives
from families without a BRCA1/2 mutation.
Risk of contralateral breast cancer depending on age at
first breast cancer
Younger age at first breast cancer was associated with a
significantly higher risk of contralateral breast cancer
Table 1 Basic characteristics of relatives and index patients from BRCA positive and negative families.
Relatives of index patients Index patients
Number of patients 6,235 6,230
Mutation status, number of patients
BRCA1 pathogenic mutation 213 1,154
BRCA2 pathogenic mutation 106 575
BRCA negative 4,326 4,501
not tested, BRCA1 family 1,046 -
not tested, BRCA2 family 544 -
Patients with contralateral breast cancer
patients from BRCA1 families 193 304
patients from BRCA2 families 56 84
patients from BRCA negative families 253 349
Median year of birth (IQR)
patients from BRCA1 families 1,943 (1933-1955) 1,960 (1952-1968)
patients from BRCA2 families 1,939 (1928-1952) 1,957 (1945-1965)
patients from BRCA negative families 1,936 (1926-1946) 1,955 (1944-1964)
Median age at first breast cancer (IQR)
patients from BRCA1 families 43.5 (37.5-51.5) 38.2 (32.8-44.4)
patients from BRCA2 families 48.1 (40.4-58.5) 42.5 (36.4-49.4)
patients from BRCA negative families 53.6 (45.3-63.9) 44.9 (37.9-51.4)
Median age at contralateral breast cancer (IQR)
patients from BRCA1 families 47.7 (40.1-55.5) 43.5 (37.7-50.5)
patients from BRCA2 families 53.1 (44.7-62.6) 47.9 (42.7-55.7)
patients from BRCA negative families 56.0 (48.5-66.6) 51.6 (45.3-59.0)
IQR, interquartile range.
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in patients from BRCA1 positive and BRCA1/2 negative
families and a trend was observed in patients from
BRCA2 positive families (Figures 3A, B and C). For
instance, after 25 years 55.1% (95%CI, 45.4% to 64.9%)
of patients from BRCA1 positive families, 38.4% (95%
CI, 18.5% to 58.2%) of patients from BRCA2 families
and 28.4% (95% CI, 20.5% to 36.3%) of patients from
non-BRCA1/2 families who were younger than 40 years
at first breast cancer developed contralateral breast
cancer. Of those who were older than 50 years of age
at first breast cancer, 21.6% (95%CI, 12.3% to 30.8%)
from families with a BRCA1 mutation, 15.5% (95% CI,
7.8% to 23.3%) from families with a BRCA2 mutation
and 12.9% (95% CI 8.9% to 17.0%) from BRCA1/2
negative families developed contralateral breast cancer
(Figure 3A, B, C). As expected the highest risks were
seen for BRCA1 mutation carriers under the age of 35
years with 15.7% (95% CI, 9.7% to 21.7%) after 5 years,
33.4% (95% CI, 24.6% to 42.1%) after 10 years, 45.3%
(95% CI, 34.8% to 55.7%) after 15 years and 61.6%
(95% CI, 49.0% to 74.1%) after 25 years. Table 2 depicts
the cumulative contralateral breast cancer risk esti-
mates for 5, 10, 15, 20, and 25 years after first breast
cancer depending on BRCA1/2 mutation status and age
at first breast cancer.
Other potential modifiers of contralateral breast cancer
risk
The number of affected family members, the age at
onset of the earliest affected family member, the number
of bilateral breast cancers in the family and PBSO were
not predictive for the occurrence of contralateral breast
cancer. The latter may be due to the fact that only 131
patients of our cohort opted for PBSO. Having only lim-
ited information on tamoxifen use which was introduced
into breast cancer treatment around 1990, we performed
a comparison of women who had their first breast can-
cer before 1990 with women who had their first breast
cancer after 1990. We could not find a significant differ-
ence in the time from first to contralateral breast cancer
between these two groups.
Discussion
Little is known about the contralateral breast cancer risk
in women with familial breast cancer that tested negative
for BRCA1 or BRCA2 mutations. Despite that lack of
knowledge, however, the demand for prophylactic bilat-
eral mastectomy after first breast cancer is increasing not
only for mutation carriers but also for women without a
BRCA1 or BRCA2 mutation [14,15]. Therefore, there is
an urgent need for empirical data that may allow women
Figure 1 Cumulative risk of contra-lateral breast cancer after first breast cancer in index cases versus relatives from BRCA1/2 positive
families and BRCA1/2 negative families.
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to base their informed decision regarding prophylactic
bilateral mastectomy on reliable risk estimates.
Contralateral breast cancer risk depending on mutation
status
Our results are concordant with a previous retrospective
study on a cohort of 327 familial non-BRCA1/2 breast
cancer cases [12,13]. These authors found incidences of
metachronous contralateral breast cancers after 10 years
that were similar to those in sporadic breast cancer
patients (that is, 6.4% versus 5.4%, respectively). They
also provided evidence that previous reports on higher
contralateral breast cancer incidence rates may have
been due to a selection bias caused by preferential DNA
testing in women with bilateral breast cancer [13].
Moreover, our calculated risks are similar to those
reported in the National Cancer Institute’s Surveillance,
Epidemiology, and End Results (SEER) database, that is,
a contralateral breast cancer risk of approximately 2.5%
to 12.6% in 10 years depending on estrogen receptor
status and age at onset [18,19]. Our data that we esti-
mated for cases from BRCA1/2 negative families are in
Figure 2 Effect of mutation status on cancer risk. Panel A shows
the cumulative distribution of the age of diagnosis at first breast
cancer. Panel B depicts the age of diagnosis at contralateral breast
cancer. Panel C represents the cumulative risk of contralateral breast
cancer after first breast cancer. Index patients were excluded.
Figure 3 Effect of age at first breast cancer on contralateral
breast cancer risk. All panels show the cumulative risk of
contralateral breast cancer after first breast cancer. Panel A: relatives
from BRCA1 positive families, Panel B: relatives from BRCA2 positive
families, Panel C: relatives from BRCA1/2 negative families. Index
patients were excluded.
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the same risk range of 7.1% (95% CI 6.0% to 8.2%) after
10 years.
Therefore, we conclude that contralateral breast can-
cer risk for familial non-BRCA1/2 breast cancer is essen-
tially in the same range as for women with sporadic
breast cancer. However, our risk estimates are in clear
contrast with the recently observed increase in prophy-
lactic bilateral mastectomy and prophylactic contralat-
eral mastectomy in women with familial breast cancer
and unknown or negative mutation status [14,15,20].
This increase may in part be due to uncertainties and
overestimations of the true risks in the case of early age
at first breast cancer or due to a positive family history,
irrespective of the mutation status [21-23].
The risks that we calculated for relatives of BRCA1 or
BRCA2 mutation carriers are in agreement with our pre-
vious report on the same but smaller cohort [5]. Our
results are further supported by results from the WECARE
study, a population-based, nested case-control study on
705 cases with contralateral breast cancer and 1,398 con-
trols with unilateral breast cancer ascertained through US
cancer registries that participated in the SEER registry sys-
tem [24]. In this study, a woman diagnosed with BRCA1
associated breast cancer between the age of 25 to 29 was
calculated to have a 5-year and 10-year risk for contralat-
eral breast cancer of 16% and 29%, respectively. This is in
line with our results, that is, a risk for contralateral breast
cancer of 15.7% (95% CI 9.7% to 21.7%) after 5 years and
33.4% (95% CI 24.6% to 42.1%) after 10 years for women
from BRCA1 positive families that developed the first
breast cancer before the age of 35 years. However, our risk
estimates are lower than those recently reported by Met-
calfe et al. in a cohort of 810 mutation carriers [10] where
the authors estimated a 15-year risk of 36.1% for BRCA1
and 28.5% for BRCA2 mutation carriers. Pierce et al. also
reported higher risk estimates with a 15-year risk of 39%
for BRCA1 and BRCA2 mutation carriers [3]. The most
likely explanation is that these studies focused on index
cases or did not exclude index cases, thereby introducing a
recruitment bias.
Modifiers of contralateral breast cancer risk
We present results which highlight that contralateral
breast cancer risk in women from BRCA1/2 negative
families depends on age at onset of first breast cancer, as
is the case for women from BRCA1 or BRCA2 positive
families. In a recent paper, Metcalfe et al. also confirmed
that the risk of contralateral breast cancer depends on age
at first diagnosis in BRCA1/2 mutation carriers. Women
older than 50 years at the time of breast cancer experi-
enced a significantly lower risk of contralateral breast can-
cer than women diagnosed before the age of 40 years (RR
0.47; 95% CI 0.47 to 0.82, P = 0.008) [10]. Metcalfe et al.
could further show that increasing numbers of affected
first degree relatives under the age of 50 years were asso-
ciated with an increased risk for contralateral breast
cancer in BRCA1 mutation carriers (RR trend 1.40; 95%
CI 1.08 to 1.81, P = 0.01) [10]. Despite extensive analyses,
Table 2 Cumulative risks (in %) and 95% confidence intervals (in parentheses) for contralateral breast cancer
depending on age at first breast cancer observed in relatives of index patients.
BRCA1 BRCA2 BRCA negative
Age at first breast cancer < 40 years
5 years after first breast cancer 14.1 (10.1-18.0) 2.9 (0.0-6.3) 4.8 (2.6-6.9)
10 years after first breast cancer 30.1 (24.0-36.2) 18.2 (7.9-28.5) 10.6 (6.8-14.4)
15 years after first breast cancer 40.8 (33.2-48.3) 20.9 (9.7-32.1) 15.3 (10.4-20.3)
25 years after first breast cancer 55.1 (45.4-64.9) 38.4 (18.5-58.2) 28.4 (20.5-36.3)
Age at first breast cancer 40-49 years
5 years after first breast cancer 9.2 (5.8-12.5) 6.9 (2.7-11.1) 4.2 (2.9-5.5)
10 years after first breast cancer 16.7 (11.7-21.7) 13.4 (7.0-19.8) 8.4 (6.3-10.5)
15 years after first breast cancer 23.2 (16.9-29.6) 22.0 (12.1-31.9) 10.7 (8.1-13.3)
25 years after first breast cancer 44.5 (33.2-55.7) 40.5 (22.4-58.6) 18.1 (13.9-22.3)
Age at first breast cancer ≥ 50 years
5 years after first breast cancer 7.1 (3.8-10.5) 3.5 (0.9-6.1) 3.6 (2.7-4.5)
10 years after first breast cancer 11.4 (6.5-16.3) 10.4 (4.9-16.0) 5.5 (4.3-6.7)
15 years after first breast cancer 18.7 (11.0-26.3) 15.5 (7.8-23.3) 8.1 (6.3-9.9)
25 years after first breast cancer 21.6 (12.3-30.8) 15.5 (7.8-23.3) 12.9 (8.9-17.0)
Total
5 years after first breast cancer 10.4 (8.3-12.5) 4.5 (2.5-6.5) 3.9 (3.2-4.6)
10 years after first breast cancer 20.4 (17.1-23.7) 13.2 (9.2-17.2) 7.1 (6.0-8.2)
15 years after first breast cancer 28.7 (24.4-32.9) 19.0 (13.5-24.4) 9.9 (8.5-11.4)
25 years after first breast cancer 44.1 (37.6-50.6) 33.5 (22.4-44.7) 17.2 (14.5-19.9)
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we could not confirm this association in our cohort.
Moreover, we could not demonstrate an effect of PBSO
on contralateral breast cancer risk as described by others
[25]. This may be explained by the fact that only 131
women opted for PBSO in this cohort.
Limitations
While the strength of our study is the large sample size,
some limitations should be mentioned. First, we cannot
rule out that phenocopies might have been included in
our analysis, since only 16% of the relatives from BRCA1
or BRCA2 positive families were proven mutation carriers.
However, Meijers-Heijboer et al. calculated a phenocopy
rate of 5% to 6% [26]. Therefore, it seems unlikely that
phenocopies had a large impact on our results. Second, we
cannot exclude a survivorship and recruitment bias. This
is supported by other studies which provided convincing
evidence for such a bias [13,26].. But as we considered
only affected relatives, including deceased patients, it is
unlikely for the survivorship and recruitment bias to have
a negative impact on our results. Besides, we cannot rule
out that the exclusion of index patients from the analysis,
which was done to avoid overestimation of risks, may have
led to an underestimation to some extent. Third, medical
reports could only be obtained from 83% of the patients.
This could have led to an incomplete ascertainment of
contralateral breast cancer. However, results from a recent
population-based study are in line with our risk estimates
for contralateral breast cancer in BRCA1 and BRCA2 car-
riers [24]. Therefore, it is unlikely that incomplete report-
ing of affected family members had a considerable
influence on our results. Fourth, the stringent selection of
high risk families, as illustrated by a 25% mutation preva-
lence in our cohort, might influence our risk estimates. In
countries where selection criteria are different, the risk
estimates for the BRCA1/2 negative families may vary
accordingly. Fifth, we could not demonstrate an effect of
further modifying factors such as PBSO, tamoxifen,
chemo- and radiation therapy on contralateral breast can-
cer due to the low uptake of these interventions or incom-
plete reporting in our cohort [3,7,9-11]. Finally, our
analysis did not consider competing cancer events. For
instance, the group specific risk estimates may be biased
to some extent by the different ovarian cancer risks in the
three groups.
Conclusions
We calculated long term risk estimates for contralateral
breast cancer in the largest cohort of women with familial
breast cancer reported so far. We demonstrate: 1) that
contralateral breast cancer risk for patients from BRCA1/2
negative families is low and similar to the risk for patients
with sporadic breast cancer; and 2) that contralateral
breast cancer risk strongly depends on the mutation status
and age at onset of the first breast cancer. This strength-
ens the importance of genetic testing as a prerequisite for
risk estimation and, consequently, informed decision mak-
ing for or against prophylactic bilateral mastectomy or
prophylactic contralateral mastectomy.
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